1Business combination agreement with Veraxa Biotech AG signed April 22, 2025, amended twice through February 2026, indicating prolonged diligence.
2IPO underwritten by Cantor Fitzgerald on August 8, 2024, with units trading as VACHU on Nasdaq, supporting ongoing trust account stability.
3Adopted clawback policy Exhibit 97.1 on March 10, 2025, fulfilling Nasdaq/Dodd-Frank compliance ahead of any potential de-SPAC.
4Shell company status confirmed with no revenue-generating operations, focused exclusively on identifying and completing initial business combination.
5Amendment No. 1 filed April 2, 2026, solely to include omitted Exhibit 97.1, with no other changes to original FY2025 10-K.